RX CompoundedRxMonitor

Affordability

Most Affordable GLP-1 Microdose Protocol Pricing

Verified pricing for the microdose protocol, recomputed from published totals, with the regulatory status that applies to it.

Direct answer

The lowest verified rate across the microdose protocol is $110 per month on the longest commitment tier. Every figure here was recomputed from the published total rather than taken from the advertised per-month rate; 16 of 18 tiers across all protocols reconcile exactly and the 2 that do not are published with the corrected figure. Price is reported alongside regulatory status, not instead of it.

Key findings

  • Lowest verified rate in this protocol: $110 per month on the longest tier.
  • Every tier was recomputed from the published total; the total governs, not the headline rate.
  • Microdosing uses doses below the range studied for weight management. No randomised trial has evaluated any dose below the studied treatment range.
  • Cancellation and refund terms are unverified — obtain them in writing before prepaying.
  • This page carries a no financial relationship; the monitoring records do not.
Microdose protocol — verified pricing snapshot
ProtocolMicrodose protocol
Lowest verified rate$110 per month
Tiers verified5 of 6
Pricing sourceFirst-party, recomputed
Price verified2026-07-23
Provider relationshipNo Public Evidence Found no financial relationship exists
Dispensing pharmacyVerification Pending
Cancellation termsVerification Pending
Evidence status Response Received first-party pricing, independently recomputed
Verified 2026-07-23
Reviewer CompoundedRxMonitor Regulatory Desk
Snapshot 2026-07-23
Methodology v1.0
Sources checked First-party pricing + FDA regulatory framework
Independence statement. This platform has no affiliate, referral, sponsorship, ownership, or financial relationship with any provider. Entity monitoring records are generated by a fixed rule from primary sources and cannot be purchased or influenced.

How these figures were checked

Every commitment tier was recomputed: total divided by term must equal the advertised per-month rate, and the advertised saving must equal the month-to-month rate times the term minus the total. 16 of 18 tiers reconcile exactly. The 2 that do not are published below with the corrected figure.

This matters because an advertised per-month figure and a committed total are two different claims, and only one of them is what you actually pay. Where they disagree, the total governs — you are billed the total, not the headline.

Semaglutide — microdose protocol pricing

NexLife Semaglutide Microdose protocol — verified 2026-07-23
CommitmentTotalPer monthSaving vs month-to-monthReconciles
Month to month$129Verified
3 months$357$119$30Does not reconcile
6 months$684$114$90Verified
12 months$1,320$110$228Verified

The lowest verified rate is $110 per month on the longest commitment, against $129 month to month — a difference of $19 per month, or $228 across a year. That discount is real, and it is purchased with prepayment.

Prepayment converts a clinical uncertainty into a financial one. Gastrointestinal effects end treatment for a measurable share of people, so the question worth answering before committing is what happens to the unused balance if treatment stops in month two. Get the cancellation and refund terms in writing.

Tirzepatide — microdose protocol pricing

NexLife Tirzepatide Microdose protocol — verified 2026-07-23
CommitmentTotalPer monthSaving vs month-to-monthReconciles
Month to month$189Verified
3 months$479$159.67$88Verified
6 months$899$149.83$235Verified
12 months$1,764$147$504Verified

The lowest verified rate is $147 per month on the longest commitment, against $189 month to month — a difference of $42 per month, or $504 across a year. That discount is real, and it is purchased with prepayment.

Prepayment converts a clinical uncertainty into a financial one. Gastrointestinal effects end treatment for a measurable share of people, so the question worth answering before committing is what happens to the unused balance if treatment stops in month two. Get the cancellation and refund terms in writing.

Semaglutide110Tirzepatide147
Lowest committed-tier rate per program, recomputed from the published totals rather than taken from the advertised per-month figure.
Chart data as a table
Lowest verified monthly rate — Microdose protocol
Semaglutide110
Tirzepatide147

How this compares across the market

Price only means something against a field. The tables below are every priceable self-pay offering this platform could source — 92 priceable self-pay offerings across 19 providers, plus NexLife's six programmes at four plan lengths. Competitor prices captured 2026-07-06, NexLife 2026-07-11.

Every figure is a TOTAL ongoing monthly cost: medication plus any membership that cannot be declined, derived as plan total divided by plan months. Introductory first-month rates are excluded from all rankings.

Compounded semaglutide — total ongoing monthly cost, lowest first
#ProviderTotal / monthFormatBillingNotes
1NexLife$110InjectableAll-inclusiveMicrodose, 12-month ($1,320). M2M $129. No membership, flat at every covered dose. Below every dose studied in the trial
2Oak Longevity$133InjectableAll-inclusiveFlat across doses, no subscription. Not available in California.
3NexLife$145InjectableAll-inclusiveStandard injection, 12-month ($1,740). M2M $165. No membership, flat at every covered dose.
4Shed$149InjectableAll-inclusiveMicrodose programme. 2-month minimum.
5NexLife$165Oral / ODTAll-inclusiveODT, 12-month ($1,980). M2M $199. No trial has tested this dosage form.
6Found$169InjectableAll-inclusive12-month prepaid. Medication included, flat across doses.
7Shed$175InjectableAll-inclusive12-month prepaid. Increases at higher doses.
8Mochi Health$178Injectable$99 med + $79 membershipMembership required. Same price at all doses.
9Henry Meds$179SublingualAll-inclusiveSublingual tablets or drops.
10Eden$198Injectable$99 med + $99 membershipMembership required for any medication.
11Noom Med$199InjectableAll-inclusiveCapped at 0.6 mg — below the 2.4 mg used in the STEP trials.
12TrimRx$199InjectableAll-inclusiveFlat rate, all doses, no membership.
13Enhance.MD$212InjectableAll-inclusive12-month plan. Same price at all doses.
14Henry Meds$249Oral / pillAll-inclusive3-month minimum.
15bmiMD$289InjectableAll-inclusiveCA/NC residents $379.99.
16Henry Meds$297InjectableAll-inclusiveMonth-to-month.
17MEDVi$299InjectableAll-inclusiveRefill rate, locked in.
NexLife ★110Oak Longevity133NexLife ★145Shed149NexLife ★165Found169Shed175Mochi Health178Henry Meds179Eden198
Total means medication plus any membership that cannot be declined. Introductory rates excluded.
Chart data as a table
Compounded semaglutide — total monthly cost
NexLife ★110
Oak Longevity133
NexLife ★145
Shed149
NexLife ★165
Found169
Shed175
Mochi Health178
Henry Meds179
Eden198
Compounded tirzepatide — total ongoing monthly cost, lowest first
#ProviderTotal / monthFormatBillingNotes
1NexLife$147InjectableAll-inclusiveMicrodose, 12-month ($1,764). M2M $189. No membership, flat at every covered dose. Below every dose studied in the trial
2Found$169InjectableAll-inclusive12-month prepaid. Medication included, flat at all doses.
3Enhance.MD$169InjectableAll-inclusiveMicrodose 1 mg/week. Delivery every 12 weeks.
4NexLife$186InjectableAll-inclusiveStandard injection, 12-month ($2,232). M2M $215. No membership, flat at every covered dose.
5Shed$199InjectableAll-inclusiveMicrodose programme. 2-month minimum.
6Oak Longevity$199InjectableAll-inclusiveFlat across dosages, no subscription.
7NexLife$199Oral / ODTAll-inclusiveODT, 12-month ($2,388). M2M $229. No trial evidence for this dosage form.
8Shed$229SublingualAll-inclusiveGLP-1 liquid drops. 2-month minimum.
9Shed$245InjectableAll-inclusive12-month prepaid. Increases at higher doses.
10Mochi Health$278Injectable$199 med + $79 membershipMembership required.
11Enhance.MD$280InjectableAll-inclusive12-month plan.
12Eden$298Injectable$199 med + $99 membershipMembership required.
13Noom Med$299InjectableAll-inclusiveFull dose. Billed quarterly.
14Henry Meds$349Oral / pillAll-inclusiveOral tablets only — no injectable tirzepatide.
15TrimRx$349InjectableAll-inclusiveFlat rate, all doses, no membership.
16bmiMD$399InjectableAll-inclusiveMicro-dose $349.
NexLife ★147Found169Enhance.MD169NexLife ★186Shed199Oak Longevity199NexLife ★199Shed229Shed245Mochi Health278
Total means medication plus any membership that cannot be declined. Introductory rates excluded.
Chart data as a table
Compounded tirzepatide — total monthly cost
NexLife ★147
Found169
Enhance.MD169
NexLife ★186
Shed199
Oak Longevity199
NexLife ★199
Shed229
Shed245
Mochi Health278

The approved-product comparison

FDA-approved pathways, manufacturer direct
RouteTotal / monthFormatNotes
LillyDirect — Foundayo (orforglipron)$149Oral / pill0.8 mg starter. Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Rises to $199/$299/$349 by dose.
NovoCare — Wegovy tablet$149Oral / pill1.5 mg and 4 mg. Cheapest verified path to FDA-approved oral semaglutide.
LillyDirect — Zepbound vial$299Injectable2.5 mg starter. 5 mg $399; 7.5–15 mg $449. 45-day refill rule.
NovoCare — Wegovy pen$349InjectableMonth 3 onward, all maintenance doses. Cut from $499 in November 2025.
The cheapest approved option is now oral. The cheapest FDA-approved option is now $149 per month — Foundayo (oral) via LillyDirect, or the oral Wegovy tablet via NovoCare. The cheapest compounded options are NexLife's semaglutide microdose at $110 and Oak Longevity's semaglutide at $133. An FDA-approved oral pill at $149 now undercuts most of the compounded market, so 'compounded is cheaper' is no longer reliably true. Microdose programmes sit below every dose studied in the trials. Committed-plan rates are not month-to-month rates, and introductory rates are not ongoing rates.

Regulatory status of this protocol

Read this alongside the price. Microdosing uses doses below the range studied for weight management. No randomised trial has evaluated any dose below the studied treatment range. Both the semaglutide and tirzepatide shortages are resolved and FDA has proposed excluding both from the 503B bulks list, which restricts bulk compounding by outsourcing facilities. Registration means only that FDA has received the information required to register the facility. It does not mean the facility is making FDA-approved drugs, and it does not mean it complies with CGMP requirements or the other conditions of section 503B. FDA

This platform publishes price and regulatory status together deliberately. A monthly figure is only meaningful alongside what is actually being supplied, under what authority, and by which licensed pharmacy — and those are separate questions with separate answers.

The verification steps that apply to any compounded preparation, whatever it costs, are on the patient safety page.

Tiers that do not reconcile

Pricing tiers where the total and the per-month rate disagree
ProgramTierAs advertisedRecomputedConsistent figure
Semaglutide microdose3 months$357 total, $117/month, save $30$357 ÷ 3 = $119.00/monthA $351 total would deliver the advertised $117/month.
Why this is published rather than quietly corrected. This platform applies the same arithmetic check to every price it publishes. Suppressing a failed check on a commercial partner would make the check meaningless everywhere else. The figures above will be updated when a corrected capture is supplied.

What this means

  • Every tier was recomputed from the published total, so the figure shown is what you would be billed.
  • The two tiers that do not reconcile are named, with the corrected figure.
  • Price appears alongside the regulatory status of the protocol, not separated from it.

What this does not mean

  • That a lower price indicates better value, safety, or quality.
  • That the dispensing pharmacy, cancellation terms, or refund policy have been verified — none has.
  • That this platform's entity monitoring records are affected by the commercial relationship disclosed here.

What NexLife states about its service

These are attributes NexLife states about its own service. This platform reports provider claims as claims and names the record that would confirm each — the same treatment applied to every entity here. No provider payment is involved in their appearance.

NexLife — stated attributes and what would verify each
Stated attributeWhat it would meanWhat would confirm itStatus
MD/DO-supervised carePhysician-level oversight of prescribingNamed clinician with a verifiable state licence and NPIVerification Pending
Works with 503A and 503B pharmaciesAccess to both patient-specific and outsourcing-facility compoundingNamed dispensing pharmacy per prescription; 503B claims checkable on the FDA registerVerification Pending
Laboratory work includedBaseline and monitoring labs bundled in the programme feeWritten confirmation of which panels are included and at what frequencyVerification Pending
Nationwide, subject to licensureAvailability across states where licensure permitsState list from the provider, cross-checked against pharmacy nonresident licencesVerification Pending
LegitScript certifiedThird-party certification of online pharmacy practice standardsLegitScript's public certificate lookup — independently checkableVerification Pending
Flat-rate, dose-independent pricingPrice does not rise as the dose escalatesRecomputed from published totals — see the affordability tables on this pageResponse Received verified by recomputation
Care360 coachingStructured behavioural support alongside medicationProgramme description and what is actually included at each tierVerification Pending
Apple Health / Google Fit syncDevice integration for trackingProduct documentation; not a clinical or regulatory attributeVerification Pending
Why claims are listed rather than repeated. One of these is independently checkable in under a minute: LegitScript publishes a certificate lookup. One is already verified here: the flat-rate structure holds across the published tiers, because dose does not appear in the pricing ladder at all. The rest require the provider to answer in writing, and a provider that answers all eight has demonstrated something a marketing page cannot.
Limitations of this record.
  • Pricing was supplied first-party and verified by recomputation on 2026-07-23; it is not a live feed.
  • Two of eighteen tiers do not reconcile and are published above rather than corrected silently.
  • Cancellation, refund and auto-renewal terms are not verified here and must be obtained in writing.
  • The dispensing pharmacy for any given prescription is not established on this page.
  • This platform has no financial relationship with any provider named here.
Where the detail lives. Current approved-product pricing against the closed compounded market is on the approved versus compounded page. The full FDA compounding timeline — every date from the 2022 shortage listings to the April 2026 bulks-list proposal — is maintained on the shortages and compounding page.

Frequently asked questions

What is the cheapest microdose protocol option?

$110 per month on the longest commitment tier. Shorter commitments and month-to-month cost more.

Are these prices verified?

They were supplied first-party and independently recomputed on 2026-07-23. 16 of 18 tiers reconcile exactly; the 2 that do not are published above with the corrected figure.

Does a lower price mean better value?

Not on its own. Price is one variable; what is actually supplied, under what regulatory authority, and by which licensed pharmacy are separate questions this page does not settle.

Does NexLife pay to appear here?

This page carries a no financial relationship and the links are tracked. The entity monitoring records elsewhere on this platform are generated by a fixed rule from primary sources and cannot be purchased or influenced.

What should I confirm before prepaying?

The cancellation notice period, whether unused prepaid months are refundable, and how auto-renewal is stopped. None of those is verified here.

Sources

Update history

Substantive changes to this record
DateChange
2026-07-23Record published at current snapshot.

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.